Status:
COMPLETED
Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Attention-Deficit/Hyperactivity Disorder
Eligibility:
All Genders
8-13 years
Phase:
PHASE2
Brief Summary
To determine whether supplementation of omega-3 long-chain polyunsaturated fatty acid conjugated to phosphatidylserine rather than triglycerides (fish oil) could affect Attention-deficit/hyperactivity...
Detailed Description
BACKGROUND Attention-deficit/hyperactivity disorder (ADHD) encompasses a broad constellation of behavioral and learning problems, clinically describes inattentive, impulsive, and/or hyperactive childr...
Eligibility Criteria
Inclusion
- 8 and 13 years of age; diagnosed as having ADHD; otherwise healthy;
Exclusion
- significant sensory or neurological limitations, epilepsy, mental retardation, psychosis, or pervasive developmental disorder; medications with known central nervous system effects such as tranquilizers, antidepressants, stimulants (including methylphenidate and amphetamines), sedating antihistamines and some asthma medications and dietary supplements but vitamins
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00382616
Start Date
July 1 2004
End Date
January 1 2005
Last Update
November 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Nutrition Unit, Sourasky Medical Center
Tel Aviv, Israel, 64239